
Topline results from the ASCERTAIN trial of the cedazuridine and decitabine combination in patients with intermediate and high-risk myelodysplastic syndromes or chronic myelomoncyctis leukemia showed that the phase III trial met its primary endpoint. The fixed-dose combination demonstrated a decitabine exposure equivalence of total 5-day dosing compared with intravenous decitabine in the study patient population.









